Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 and Atezolizumab in Advanced Solid Tumors
NCT07407933Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 9
01
Overview
A Phase 2 trial of YL201 in Small Cell Lung Cancer (SCLC), sponsored by MediLink Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
YL201
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT07407933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407933.